Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study

Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study

Long-acting (LA) antiretroviral therapies for human immunodeficiency virus (HIV), such as injectable formulations of cabotegravir and rilpivirine (CAB+RPV LA), are now available. Considering the limited data on the out-of-hospital administration of this combination, evaluating the implementation str...

Full description

Saved in:
Bibliographic Details
Main Authors: Diana Hernández-Sánchez, Juan M. Leyva-Moral, Julian Olalla, Eugènia Negredo, on behalf of the HOLA Study Group
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Viruses
Subjects:
HIV
antiretrovirals
cabotegravir + rilpivirine long acting
out-of-hospital administration
implementation
barriers and facilitators
Online Access:https://www.mdpi.com/1999-4915/17/7/993
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items